Aquestive Therapeutics Inc

Stage 2 advancing remains intact despite the late‐June exhaustion signal. Price has retraced into the rising 9/21/50 EMA confluence on neutral RSI and OB/OS context, offering a disciplined entry. Speculative intent favors buying this pullback while preserving the uptrend and monitoring for an EMA breach.

• ↑Q1 2026 revenue rose 66% YoY to $14.4M, driven by license and manufacturing revenues.
• ↑Anifilm is the first sublingual epinephrine, targeting unmet patient preference for oral therapy.
• ↓Potential advisory committee meeting could delay FDA approval of Anifilm.